SLC5A2 and cognitive disorder: SGLT2 inhibitors expand the therapeutic approaches for cognitive disorders by reducing neuroinflammation, enhancing cerebral glucose metabolism and energy availability, limiting amyloid production and aggregation, and modulating neurotrophic factor production to support neural regeneration [17].